Fertility / Penetro-X


Penetro-x is the newest fertility supplement, which has been proven the great efficacy on semen parameters of infertile men as the number of sperms, motility, and normal forms.

Penetro-x has a unique formula; in addition to the well-known ingredients for healthy sperm, it has a new component that helps and improves all sperm parameters with a very high percentage.

Bilpharma, Penetro-x has provided innovative unique formula, It is an OTC nutritional supplement developed and proven to improve male fertility in at least 3 months (the length of time necessary for mutation of spermatozoa).

Clinical studies have found that the ingredients of Penetro-x support normal sperm development, maintain sperm quality, and target multiple sperm functions.

In actual patient testing, following 3 months of Penetro-x use, it was revealed that sperm count had increased 11 times. But, for maximum benefit, it is recommended that Penetro-x be taken for six months.

Pentro-x is manufactured in an FDA (USA) and GMP (Canada) registered facility and has supported men’s health for decades.

  • Indications:
    • Male Infertility due to:
      • Impaired semen quality
      • Oligozoospermia
      • Asthenozoospermia
      • Teratozoospermia
      • OAT- Syndrome ( Oligoasthenoteratozoospermia)
      • DNA fragmentation
      • Erectile Dysfunction
      • Antioxidative therapy after varicocelectomy
  • Benefit
  • Increase sperm count
    • Support sperm quality
    • Promote sperm motility
    • Improve sperm morphology
    • Positively affects DNA fragmentation And Improves male sexual function with absolutely no reported side effects of any kind
    • Doesn’t have side effects of Hormones and other medication.
  • Dose:    
    • 2 capsules two times daily with meals or as directed by a healthcare professional

*Penetro-x  made in Canada. 

*Product of Bilpharma Inc, Canada.


  • Oral administration of 500 mg arginine-HCl per day to infertile men for 6-8 weeks markedly increased sperm counts and motility in a majority of patients and resulted in successful pregnancies. (83) Similar effects on oligospermia and conception rates have been reported in other preliminary trials. Alternative Medicine ReviewDec 2002 by Jeremy Appleton.
  • We can conclude that under the conditions of this study, the addition of L-arginine and polyamines to human sperm cells obtained from idiopathic or diabetic asthenozoospermic patients showed a beneficial effect on sperm motility. Ginecol Obstet Mex. 2003 Jun;71:297-303
  • Semen analysis data showed a significant increase in concentration, motility, vitality, and morphology parameters. Our results suggest that antioxidant treatment improves sperm quality not only in terms of key seminal parameters and basal DNA damage but also helps to maintain DNA integrity. Andrologia. 2013 Jun;45(3):211-6. doi: 10.2221/and.12003. Epub 2012 Sep 3.
  • A favorable effect of the compound on sperm motility and rapid linear progression has been shown in 37 out of 47 patients treated. In addition, the total number of sperms increased. Drugs Exp Clin Res. 1995;21(4):157-9.
  • Combined L-carnitine and acetyl-L-Carnitine have a supplementary effect in the treatment of idiopathic asthenospermia and improve the semen quality of the patient. Zhonghua Nan Ke Xue. 2008 Feb;14(2):149-51.
  • The administration of LC and LAC is effective in increasing sperm kinetic features in patients affected by idiopathic asthenozoospemia and improves the total oxyradical scavenging capacity of the seminal fluid in the same population. Fertil Steril. 2005 Sep;84(3):662-71.
  • Spermatozoa undergo a series of changes before and during egg binding to acquire the ability to fuse with the oocyte. These priming events are regulated by the activation of compartmentalized intracellular signaling pathways, which control the phosphorylation status of sperm proteins. Increased protein tyrosine phosphorylation is associated with capacitation, hyperactivated motility, zona pellucida binding, acrosome reaction, and sperm-oocyte binding and fusion. 2003 Jan;125(1):17-26: Protein phosphorylation in mammalian spermatozoa
  • L-carnitine in idiopathic asthenozoospermia: a multicenter study. Italian Study Group on Carnitine and Male Infertility. Costa M, Canale D, Filicori M et al. Andrologia. 1994 May-Jun; 26(3):155-159.
  • L-carnitine Supplemented Extender Improves Cryopreserved-thawed Cat Epididymal Sperm Motility.  Manee-In S, Parmornsupornvichit S, Kraiprayoon S, Tharasanit T, Chanapiwat P, Kaeoket K.Asian-Australas J Anim Sci. 2014 Jun; 27(6):791-6.  
  • Influence of various substrates on the acetylcarnitine: carnitine ratio in motile and immotile human spermatozoa. Golan R, Shalev DP, Wasserzug O et al. J Reprod Fertil. 1986; 78(1):287-293.
  • The effect of oral selenium supplementation on human sperm motility. Scott R, et al. Br J Urol 1998; 82:76-80.
  • Male factor subfertility: possible causes and the impact of nutritional factors. Wong WY, Thomas CM, Merkus JM, et al. Fertil Steril. 2000 Mar; 73(3):435-442. Review
  • Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Wong WY, Merkus HM, Thomas CM et al. Fertil Steril. 2002; 77(3):491-498.
  • Carnitines and male infertility.  Agarwal A, Said TM. Reproductive Biomedicine Online. 2004; 8(4):376-84.
  • Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia. Cavallini G, Ferraretti AP, Gianaroli L et al. J Androl. 2004 Sep-Oct;25(5):761-770.
  • A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and lacetyl-carnitine treatment in men with asthenozoospermia. Lenzi A, Sgro P, Salacone P et al. Fertil Steril. 2004 Jun;81(6):1578-1584.
  • Oral carnitine supplementation increases sperm motility in asthenozoospermic men with normal sperm phospholipid hydroperoxide glutathione peroxidase levels. Garolla A, Maiorino M, Roverato A et al. Fertil. Steril. 2005 Feb; 83(2):355-361.
  • Evidence for decreasing quality of semen during the past 50 years.  Carlsen E. et al., BMJ 305 (1992): 609-13
  • World Health Organization reference values for human semen characteristics. Cooper TG et al., Human Reproduction Update. 2010; 16.3: 231-245
  • The role of antioxidant therapy in the treatment of male infertility. Agarwal A & Sekhon LH, Human Fertility. 2010; 13(4): 217-225
  • Effects of treatment with carnitines in infertile patients with prostato-vesiculo-epididymitis  Vicari E, Calogero AE. Human Reproduction. 2001; 16(11):2338-2342
  • Antioxidant treatment with carnitines is effective in infertile patients with prostatovesiculoepididymitis and elevated seminal leukocyte concentrations after treatment with nonsteroidal anti-inflammatory compounds.  Vicari E, La Vignera S, Calogero AE. Fertil Steril. 2002; 78(6):1203-1208
  • Varicocele is associated with elevated spermatozoal reactive oxygen species production and diminished seminal plasma antioxidant capacity Hendin BN, Kolettis PN, Sharma RK, et al.  J Urol. 1999 Jun;161(6):1831-1834
  • Effect of ascorbic acid supplementation on the sperm quality of smokers. Dawson EB et al. Fertil. Steril. 1992 Nov;58(5):1034-1039.
  • Effect of seminal oxidative stress on fertility after vasectomy reversal.Kolettis PN, Sharma RK, Pasqualotto FF et al. Fertil. Steril. 1999 Feb;71(2):249-255,
  • Seminal reactive oxygen species and sperm motility and morphology in men with spinal cord injury. Padron OF, Brackett NL, Sharma RK et al. Fertil Steril. 1997 Jun; 67(6):1115-1120.
  • Role of reactive oxygen species in male infertility. Sharma RK, Agarwal A. Urology. 1996 Dec; 48(6):835-850. Review
  • Seminal oxidative stress in patients with chronic prostatitis. Pasqualotto FF, Sharma RK, Potts JM et al. Urology. 2000 June; 55(6):881-885
  • A novel association between sperm reactive oxygen species production, sperm morphological defects, and the sperm deformity index. Aziz N, Saleh RA, Sharma RK et al. Fertil. Steril. 2004 Feb; 81(2):349-354.